Cargando…
Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
AIM: We aimed to provide real-life data on the outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus as second-line treatment after failure of first-line pazopanib. PATIENTS AND METHODS: Data from the medical charts of mRCC patients from 8 centers in Greece and Spain we...
Autores principales: | Koutsoukos, Konstantinos, Bamias, Aristotelis, Tzannis, Kimon, Espinosa Montaño, Marta, Bozionelou, Vasiliki, Christodoulou, Christos, Stefanou, Dimitra, Kalofonos, Haralabos, Duran, Ignacio, Papazisis, Konstantinos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640393/ https://www.ncbi.nlm.nih.gov/pubmed/29062235 http://dx.doi.org/10.2147/OTT.S141260 |
Ejemplares similares
-
Referral for “Neoadjuvant Chemotherapy” for Muscle-Invasive Bladder Cancer to a Multidisciplinary Board: Patterns, Management and Outcomes
por: Dellis, Athanasios, et al.
Publicado: (2021) -
Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017) -
The Development of an Angiogenic Protein “Signature” in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling
por: Trachana, Sofia-Paraskevi, et al.
Publicado: (2016) -
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
por: Bamias, Aristotelis, et al.
Publicado: (2023) -
Clinical Perspectives of ERCC1 in Bladder Cancer
por: Koutsoukos, Konstantinos, et al.
Publicado: (2020)